India IPO
✅ CURRENT IPO
IPO UPDATES

Amanta Healthcare Ltd IPO GMP, Date, Price Band & Review

manta Healthcare IPO ; IPO date. 01st – 03rd Sep 2025 ; Listing date. 09 Sep 2025 ; Price range. ₹120 – ₹126. Lot size 119 — ₹14994 ; Issue size. 126cr.

IPO Details
Amanta Healthcare Ltd IPO

Amanta Healthcare Ltd IPO

Amanta Healthcare Ltd IPO Details

DetailDescription
IPO DateSeptember 1, 2025 to September 3, 2025
Listing Date-
Face Value₹ 10 per share
Issue Price Band₹ 120 to ₹ 126 per share
Lot Size119 Shares
Sale TypeFresh Capital
Total Issue Size1,00,00,000 shares (aggregating up to ₹ 126.00 Cr)
Issue TypeBookbuilding IPO
Listing AtBSE, NSE
Share Holding Pre Issue2,88,29,351 shares
Share Holding Post Issue3,88,29,351 shares

About Amanta Healthcare Ltd IPO

Amanta Healthcare IPO opens on September 1, 2025 and closes on September 3, 2025, at ₹120–₹126 per equity share with a face value of ₹10. The company is looking to raise ₹126 crore (approx) via a 100% fresh issue of 1.00 crore equity shares of ₹10 face value and there is no offer for sale. The lot size is 119 shares per application and category allocation of 50 percent for QIB, 15 percent for NII and 35 percent for retail for the net issue. As per the tentative schedule of the issue, the basis of allotment will be on September 4, refunds and credit to the account on September 5 and listing on BSE and NSE on September 8, 2025. Beeline Capital Advisors is the book-running lead manager and MUFG Intime India is the registrar of the IPO.

Company Background

Amanta Healthcare IPO is a manufacturer that is focused on sterile liquid products, particularly LVPs and SVPs, made on Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blowing Moulding (ISBM) lines. The Company had a total of seven parenteral lines (four Large Volume parenterals and 3 small volume parenterals) at a WHO-GMP certified unit having 66,852 sq. meters at Hariyala, District Kheda, State of Gujarat as of 31 December 2024. The sales for FY25 came in at ₹276.09 crore and profit after tax at ₹10.5 crore – indicating a strong improvement in performance on a YoY basis, while key to that has been a broader execution push.

Operations & Product Range

Amanta manufactures more than 45 generics for six categories, from fluid therapy, ophthalmics, respiratory care, irrigation solutions, to other related sterile solutions in container volumes ranging from 2 ml up to 1000 ml and closure options. It has 1,727 employees (including 509 full-time employees) and has exclusive F&D space and quality control laboratories manned by 128 professionals, which depicts the emphasis on sterile production controls. Its commercial footprint includes domestic and export businesses with regulatory filings and product registrations to ensure market access and security of supply.

Facility & Production

The manufacturing facility of Amanta Healthcare IPO is located in Hariyala, Kheda WHO-GMP certified plant, where it has 4 LVP Lines and 3 SVP Lines for Aseptic liquid filling technology with the help of ABFS and ISBM. The features are suitable for multiple fill volumes and closure systems while providing the required therapy breadth and packaging flexibility for hospital and retail channels. In-house F&D, QC and QA teams are further strength to production’s bottom which is charged with Process validation, sterility assurance & batch release requirements for sterile injectables.

Brands & Market Presence

Amanta caters to hospitals, trade channels and collaborated pharmaceutical companies all over India with presence across 316 stockists supported with 108 field personnel for domestic coverage. The company's global footprint is reported in 19 unique countries across 112 jurisdictions and 47 products registered, indicating a focus on regulatory filings and dossier-based market entry. Apart from own-label supplies, Amanta associates with Indian and multinational pharma companies for commercial-line and license-based deals, thus providing increased visibility and recurring business.

Revenue Channels

  • Sale of LVPs and SVPs (e.g., fluid therapy, ophthalmic, respiratory, irrigation solutions) to hospitals, institutions and trade networks in India.
  • Exports of sterile liquid products into 19 countries through product registrations covering 112 jurisdictions.
  • Contract manufacturing and license-based commercial supply partnerships with Indian and global pharmaceutical companies.

Management & Shareholding

Amanta Healthcare IPO management is promoter-driven with the help of heads of manufacturing, quality, regulatory, finance and sales to run sterile operations at scale. Credit metrics are expected to improve through FY24 with leverage and coverage ratios and sufficient liquidity and a stable working capital cycle, in line with additional growth investments ahead of capacity additions.

Promoters & shareholding

The promoters of Amanta Healthcare IPO are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendrakumar Patel and Milcent Appliances Private Limited, who are holding the management leash by having significant control over the strategic and operational functions. The IPO is a fresh issue of 1.00 crore shares that would lead to a dilution of promoter holding in line with the capitalisation of the company and will keep promoter anchor investors' interest in strategic decisions after listing.

Board Members

The board of Amanta Healthcare IPO is a mix of promoter directors & professional management and it is expected to have committees for audit, nomination & remuneration and stakeholder relations as per the mainboard governance requirements.

Objectives of Amanta Healthcare IPO

  • Capex of ₹70 cr to set up a new manufacturing line of SteriPort to enhance sterile capacity and product width.
  • A Capex of ₹30.13 crore toward building and equipment for a new SVP line to increase capacity and SKU flexibility.
  • Balance for general corporate purposes, including systems, talent and operating resilience during scale-up.

Conclusion

The Amanta Healthcare IPO is expected to raise about ₹126 crore at a price band of ₹120-126 per share through 100% FII, which will be invested in setting up new sterile capacity in SteriPort and SVP lines. The company’s WHO-GMP-validated plant, seven-line sterile platform and mix of own-label and partnered supply across India and export markets leave it well-positioned to compound volumes as new lines come online. For investors following healthcare manufacturing, sterile capabilities, track record of registrations and growth capex provide an easy-to-follow roadmap to hitting the FY26 targets.

Amanta Healthcare Ltd IPO Financial Information

Latest Revenue

276.09

₹ Crore

Profit After Tax

10.5

₹ Crore

Net Worth

96.39

₹ Crore

Total Borrowing

195

₹ Crore

Period EndedAssetsRevenue From OperationsProfit After TaxNet WorthTotal Borrowing
31 Mar 2025381.76276.0910.596.39195
31 Mar 2024352282466205.23
31 Mar 2023374.06262.7-2.1162.88215.66
Amount in ₹ Crore

Amanta Healthcare Ltd Key Performance Indicator

KPIValues
ROE12.42%
ROCE13.72%
Debt/Equity2.02
RoNW10.89%
PAT Margin3.86%
EBITDA Margin22.11%
Price to Book Value3.77
Pre IPOPost IPO
EPS (Rs)3.643
P/E (x)34.5947

Frequently Asked Questions

The IPO opens on September 1, 2025 and closes on September 3, 2025.
About ₹126 crore via a 100% fresh issue of 1.00 crore equity shares; there is no OFS.
The lot size is 119 shares per application.
Sterile liquid products, including IV fluids, ophthalmic solutions, respiratory care products, diluents and irrigation solutions made using ABFS and ISBM.
Published By
India IPO Editorial Team

The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.

Competitive Strengths

1

Focused sterile liquid platform with seven parenteral lines (4 LVP, 3 SVP) operating within a WHO-GMP certified facility at Hariyala, Gujarat.

2

Technology based on ABFS and ISBM for sterile filling of multi-volume formats (2ml to 1000ml) and closures for 45+ products.

3

Domestically widespread presence with 316+ stockists and a 108-strong sales team, in addition to 19 export markets covering 112 jurisdictions.

4

Partnership-based model with Indian and MNC pharma companies for contract manufacturing & license-based supply and to promote use and recurring revenues.

Official Documents

Download regulatory filings

Amanta Healthcare Ltd IPO Timeline

IPO Open DateMon, Sep 1, 2025
IPO Close DateWed, Sep 3, 2025
Tentative AllotmentThu, Sep 4, 2025
Initiation of RefundsMon, Sep 8, 2025
Credit of Shares to DematMon, Sep 8, 2025
Tentative Listing DateTue, Sep 9, 2025
Cut-off time for UPI mandate confirmation5 PM on September 3, 2025

IPO Lot Size

InvestorsNo.of lotsShares OfferedMax Bid Amount
Retail (Min)1119₹14,994
Retail (Max)131,547₹1,94,922
S-HNI (Min)141,666₹2,09,916
S-HNI (Max)667,854₹9,89,604
B-HNI (Min)677,973₹10,04,598